Endo Pharmaceuticals (ENDP) and Impax Laboratories (IPXL) Seen as Future Leaders of Specialty Pharma at Guggenheim
Tweet Send to a Friend
Guggenheim analyst Louis Chen offered some positive commentary on Buy-rated Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) ($100 pt) and Impax ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
